Roblitinib

Overview

Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC 50 of 1.9 nM. Roblitinib has antitumor activity.

Application

Products | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > FGFR

Product Information

• Catalog No.: HY-101568
• CAS No.: 1708971-55-4
• Molecular Formula: C25H30N8O4
• Molecular Weight: 506.56
• Purity: 99.67%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source